UNSPSC 51294409: Piberaline

This classification denotes an antidepressant agent with the molecular formula C17H19N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8M09P36809, chemically known as piperazine, 1-(phenylmethyl)-4-(2-pyridinylcarbonyl)- but generally known as piberaline, which bears US NIH Compound Identifier 65975. European Medicines Agency schedules Piberaline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09804MIG.

UNSPSC 51294409 Piberaline is a Commodity code, but the recent state and local opportunities tagged under it do not procure piberaline; instead, they solicit naloxone, safe drug deactivation systems, and broader pharmaceutical and over-the-counter products. State and local governments are using this code to source emergency response medications, harm-reduction systems, and generic pharmaceuticals through competitive bidding and cooperative purchasing agreements. The issuing bodies span county health departments, state pharmacy benefit programs, and multistate cooperative purchasing alliances. Work ranges from annual naloxone procurement for community health initiatives to large-scale generic pharmaceutical supply agreements covering multiple states and local government facilities.

Activity appears concentrated in Florida, Texas, and Minnesota as of mid-2026. Seminole County, Florida issued an IFB (solicitation IFB60459723LAS, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford. The Texas Health and Human Services Commission released an RFI (HHS0017013, posted April 3, 2026) to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and wholesaler channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers, with awards effective July 1, 2026 and participation extending to Oregon. The mismatch between the code name and actual procurement scope suggests either a taxonomy misclassification in the state and local system or use of the code as a catch-all for pharmaceutical commodities beyond piberaline specifically.